Correction to “Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach”

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-09-09 DOI:10.1002/cam4.70174

引用次数: 0

Abstract

Islam S, Amin MA, Rengasamy KRR, Mohiuddin AKM, Mahmud S. Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach. Cancer Med. 2024;13(15):e70074. doi:10.1002/cam4.70074.

A second affiliation has been added for Kannan R. R. Rengasamy and reads as follows:

³Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.

An acknowledgment section has been added and reads as follows:

Kannan R.R. Rengasamy acknowledges the Centre for High Performance Computing (CHPC), South Africa, for providing computational resources to this research project.

We apologize for this error.

查看原文本刊更多论文

更正 "基于结构的药代动力学模型用于精确抑制乳腺癌中的突变 ESR2：系统计算方法"。

Islam S、Amin MA、Rengasamy KRR、Mohiuddin AKM、Mahmud S.基于结构的乳腺癌突变 ESR2 精准抑制药理模型：系统计算方法。Cancer Med.Doi:10.1002/cam4.70074.A second affiliation has been added for Kannan R. R. Rengasamy and reads as follows: 3Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.添加了致谢部分，内容如下：Kannan R.R. Rengasamy 感谢南非高性能计算中心 (CHPC) 为本研究项目提供计算资源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.